Overview

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Disufenton sodium